Summary of intraoperative indices
| Intraoperative indices | Studies (n) | Sample size | RR (CI) | WMD (CI) | I2 (%) | P of χ2 | Selected model | P for overall effect | |
| Anti-VEGF group | No anti-VEGF group | ||||||||
| Duration of surgery | 7 (overall) | 111 | 107 | NA | –18.277 (–29.287 to –7.267) | 90.20 | 0.01 | Random-effect | 0.001 |
| 5 (bevacizumab) | 78 | 74 | NA | – 23.858 (–28.198 to –19.518) | 45.2 | >0.1 | Fixed-effect | <0.05 | |
| 1 (conbercept) | 18 | 18 | NA | –10.000 (–15.916 to –4.084) | – | – | Fixed-effect | <0.05 | |
| 1 (ranibizumab) | 15 | 15 | NA | 12.000 (4.038 to 19.962) | – | – | Fixed-effect | >0.05 | |
| Intraoperative bleeding | 5 | 158 | 145 | 0.531 (0.440 to 0.642) | NA | 92.2 | 0.001 | Random-effect | 0.001 |
| Frequency of required endodiathermy | 10 | 172 | 165 | 0.212 (0.126 to 0.362) | –1.297 (–1.590 to –1.004) | <50 | >0.1 | Fixed-effect | 0.001 |
| Intraoperative iatrogenic retinal breaks | 6 (overall) | 130 | 128 | 0.422 (0.156 to 1.145) | NA | 60.7 | 0.02 | Random-effect | 0.09 |
| 4 (bevacizumab) | 97 | 95 | 0.351 (0.149 to 0.781) | NA | 0 | 0.451 | Fixed-effect | <0.05 | |
| 1 (conbercept) | 18 | 18 | 0.143 (0.008 to 2.581) | NA | – | – | Fixed-effect | >0.05 | |
| 1 (ranibizumab) | 15 | 15 | 0.806 (0.613 to 1.060) | NA | – | – | Fixed-effect | >0.05 | |
| Frequency of required relaxing retinotomy | 5 | 104 | 104 | 0.378 (0.154 to 0.929) | NA | 0 | 0.769 | Fixed-effect | 0.034 |
| Rate of endotamponade with silicone oil | 7 | 134 | 128 | 0.430 (0.188 to 0.981) | NA | 69.1 | 0.002 | Random-effect | 0.045 |
NA, not available; RR, relative risk; VEGF, vascular endothelial growth factor; WMD, weighted mean difference.